MTHFR gene polymorphisms and methotrexate toxicity in adult patients with hematological malignancies: a meta-analysis. (June 2016)

• Record Type: Journal Article
• Authors: Zhao, Ming; Liang, Liang; Ji, Liwei; Chen, Di; Zhang, Yatong; Zhu, Yuanchao; Ongaro, Alessia
• Is Part Of: Pharmacogenomics. Volume 17:Number 9(2016)
• Page Start: 1005
• Page End: 1017
• Publication Date: 2016-06
• Subjects: adult -- hematological malignancy -- MTHFR -- polymorphism -- toxicity; Pharmacogenomics -- Periodicals; 615.1
• DOI: 10.2217/pgs-2016-0004
• Languages: English
• ISSNs: 1462-2416

Abstract

Background: MTHFR gene polymorphisms has been shown to be associated with methotrexate (MTX) toxicity in adult hematological malignancies; however, the results remain inconclusive.Materials & methods: To examine the role of common MTHFR variants in MTX toxicity prediction, we performed a meta-analysis via identifying relevant studies for quantitative data pooling.Results: Our results showed a significant association between MTHFR C677T polymorphism and increased risk of MTX-induced all-grade (grade 1–4) and severe (grade 3–4) hepatic and gastrointestinal toxicities in Caucasian independent of MTX dosage. MTHFR 677T allele increased risk of severe mucositis and all-grade hematological toxicity. MTHFR A1298C polymorphism was not significantly associated with hepatic and hematological toxicity, whereas perhaps having a protective effect on mucositis and gastrointestinal toxicity.Conclusion: MTHFR C677T polymorphism may be a good predictor for MTX toxicity in adult hematological malignancies.